(Q36892617)

16 August 2017

1 reference

title

A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia (English)

1 reference

hypereosinophilic syndrome

16 August 2017

main subject

1 reference

4

Hagop Kantarjian

1 reference

16 August 2017

5

Srdan Verstovsek

1 reference

16 August 2017

3

Radovan Vrhovac

1 reference

16 August 2017

Matko Kalac

1

1 reference

16 August 2017

Alfonso Quintás-Cardama

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

110

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

955-964

1 reference

NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

Treatment of the Hypereosinophilic Syndrome with Interferon-α

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Atypical myeloproliferative disorders: diagnosis and management

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Molecular classification and pathogenesis of eosinophilic disorders: 2005 update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Cytogenetic and molecular genetic aspects of eosinophilic leukaemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Hypereosinophilic syndrome terminating in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Abnormal Clones of T Cells Producing Interleukin-5 in Idiopathic Eosinophilia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Human TH1 and TH2 subsets: doubt no more

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Modern diagnosis and treatment of primary eosinophilia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Eosinophilia: secondary, clonal and idiopathic

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Interferon-alpha for the hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Sustained remission of idiopathic hypereosinophilic syndrome following alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Response of six patients with idiopathic hypereosinophilic syndrome to interferon alfa

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

alpha-Interferon treatment for idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Cyclosporin for hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Treatment of hypereosinophilic syndrome in a child using cyclosporine: implication for a primary T-cell abnormality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplant

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Chronic myeloproliferative disorders: a tyrosine kinase tale.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Treatment of hypereosinophilic syndrome with imatinib mesilate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Resistance to tyrosine kinase inhibitors: calling on extra forces

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Receptor tyrosine kinase mutations in myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

The second generation of BCR-ABL tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

AMN107: tightening the grip of imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

New assignments for multitasking signal transduction inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Targeted therapy for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Use of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22920

7 January 2021

Identifiers

DOI

10.1002/CNCR.22920

1 reference

16 August 2017

1 reference